2026年11月4日星期三
M
Przegląd Świata
Światowe skróty
New MUFG digital bank to forgo ATM cards in cybercrime safeguard— 日经 Nikkei AsiaJapan to bolster defenses with unified missile, artillery systems— 日经 Nikkei AsiaNTT to help Japanese companies update at-risk aging IT with AI— 日经 Nikkei Asia5 things to know about the US midterms and what they mean for Asia— 日经 Nikkei AsiaChina's cable-cutting threat reaches Taiwan and the Philippines— 日经 Nikkei AsiaVienna entrepreneur takes leaders on lux train to China to foster ties— 日经 Nikkei AsiaBangladesh garment factories become second schools for women— 日经 Nikkei AsiaThailand to raise tax on imported EVs to 35% as Chinese brands gain ground— 日经 Nikkei AsiaNew MUFG digital bank to forgo ATM cards in cybercrime safeguard— 日经 Nikkei AsiaJapan to bolster defenses with unified missile, artillery systems— 日经 Nikkei AsiaNTT to help Japanese companies update at-risk aging IT with AI— 日经 Nikkei Asia5 things to know about the US midterms and what they mean for Asia— 日经 Nikkei AsiaChina's cable-cutting threat reaches Taiwan and the Philippines— 日经 Nikkei AsiaVienna entrepreneur takes leaders on lux train to China to foster ties— 日经 Nikkei AsiaBangladesh garment factories become second schools for women— 日经 Nikkei AsiaThailand to raise tax on imported EVs to 35% as Chinese brands gain ground— 日经 Nikkei Asia

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial

Źródło Nature 生命科学1 dni temu
Streszczenie treści

Ta strona udostępnia jedynie indeks tytułów i streszczeń; pełna treść i prawa autorskie należą do pierwotnego wydawcy. Kliknij link do oryginału, aby przeczytać.

Przejdź do oryginału
Kanał przynależności
Nauka
Region przynależności
Perspektywa globalna
Język oryginału
English
Numer pozycji
science-f81c0280

Comments 0 comments

No comments yet. Be the first.

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial · Przegląd Świata